These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 17208435

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL, Andersson M, Kamby C.
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [Abstract] [Full Text] [Related]

  • 6. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J, Arteaga CL.
    J Clin Oncol; 2005 Apr 10; 23(11):2445-59. PubMed ID: 15753456
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY, Bang YJ.
    Cancer Lett; 2008 Dec 18; 272(2):296-306. PubMed ID: 18774637
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S, Ostman A, Rollman O.
    Arch Dermatol Res; 2008 Oct 18; 300(9):505-16. PubMed ID: 18446355
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.
    Int J Biochem Cell Biol; 2007 Oct 18; 39(7-8):1416-31. PubMed ID: 17596994
    [Abstract] [Full Text] [Related]

  • 13. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL.
    Oncogene; 2005 Sep 15; 24(41):6213-21. PubMed ID: 16091755
    [Abstract] [Full Text] [Related]

  • 14. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H.
    Adv Ther; 2009 Mar 15; 26(3):263-71. PubMed ID: 19365626
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL, Xia W, Spector NL.
    Clin Cancer Res; 2008 Nov 01; 14(21):6730-4. PubMed ID: 18980964
    [Abstract] [Full Text] [Related]

  • 18. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
    Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, Smykla RA, Mastalerz H, Fink BE, Hunt JT, Gavai AV, Vite GD.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6186-93. PubMed ID: 17062696
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R.
    Biochem Biophys Res Commun; 2004 Jun 18; 319(1):1-11. PubMed ID: 15158434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.